Biogen BIIB Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 301.8%-0.1pp | 301.9%-0.4pp | 302.4%-0.3pp | 302.7%-0.1pp | 302.8%+0.5pp | |
| Net margin | 59.2%-0.8pp | 59.9%-3.3pp | 63.2%-0.8pp | 64.1%+3.3pp | 60.7%+3.0pp | |
| Returns | ||||||
| Return on equity | 34.1%-1.2pp | 35.3%-2.7pp | 38%-1.2pp | 39.2%+1.5pp | 37.7%+1.1pp | |
| Return on invested capital | 31.6%-0.4pp | 32%-1.5pp | 33.5%-0.3pp | 33.8%+1.2pp | 32.6%+1.2pp | |
| Efficiency | ||||||
| Asset turnover | 1.4×0.0× | 1.4×0.0× | 1.4×0.0× | 1.4×0.0× | 1.4×0.0× | |
| Liquidity | ||||||
| Current ratio | 11×+1.6× | 9.3×+1.3× | 8×+1.5× | 6.6×+0.2× | 6.3×-0.7× | |
| Leverage | ||||||
| Debt-to-equity | 1.5×+0.1× | 1.4×0.0× | 1.4×+0.1× | 1.4×0.0× | 1.4×-0.2× | |
| Net debt / EBITDA | 4.9×+0.3× | 4.6×-0.2× | 4.8×-0.2× | 5×-0.9× | 5.9×-1.9× | |
| Per Share | ||||||
| Book value per share | $493.78+2.0% | $483.91+2.0% | $474.37+2.6% | $462.56+2.5% | $451.26+2.6% | |
| Valuation | ||||||
| Market capitalization | $91.77B+8.1% | $84.89B+4.3% | $81.36B-8.6% | $89.06B-14.6% | $104.3B-9.8% | |
| Price / earnings | 63×+5.4× | 57.6×+5.6× | 52.1×-4.7× | 56.8×-17.0× | 73.8×-13.3× | |
| Price / sales | 9.2×+0.7× | 8.5×+0.3× | 8.2×-0.9× | 9.1×-1.6× | 10.8×-1.2× | |
| Price / book | 5×+0.3× | 4.8×+0.1× | 4.7×-0.6× | 5.3×-1.1× | 6.4×-0.9× | |
| EV / EBITDA | 38.8×+2.8× | 36.1×+1.8× | 34.3×-3.4× | 37.8×-10.3× | 48.1×-9.7× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Biogen's profit margins?
- Biogen (BIIB) runs a 75.5% gross margin and a 22.9% operating margin, with a 14.3% net margin.
- Where do Biogen's ratios come from?
- Every ratio is computed from Biogen's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
